Carregant...

Phase 1 combination study of Eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer

Eribulin mesylate (Halaven®) is a novel inhibitor of microtubule dynamics that has demonstrated a survival benefit in patients with locally recurrent or metastatic breast cancer who previously received at least two chemotherapeutic regimens including an anthracycline and a taxane. Although trastuzum...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Invest New Drugs
Autors principals: Mukai, Hirofumi, Saeki, Toshiaki, Shimada, Ken, Naito, Yoichi, Matsubara, Nobuaki, Nakanishi, Tadashi, Obaishi, Hiroshi, Namiki, Masayuki, Sasaki, Yasutsuna
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2014
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4295025/
https://ncbi.nlm.nih.gov/pubmed/25242374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0161-y
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!